Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 1;5(4):859-878.
doi: 10.1016/j.path.2012.08.004.

Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus

Affiliations

Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus

Bojana Djordjevic et al. Surg Pathol Clin. .

Abstract

A number of different clinical scenarios are presented in which lab-based analyses beyond the usual diagnosis based on light microscopic examination of H&E stained slides - immunohistochemistry and PCR-based assays such as sequencing, mutation testing, microsatellite instability analysis, and determination of MLH1 methylation - are most helpful for guiding diagnosis and treatment of endometrial cancer. The central goal of this information is to provide a practical guide of key current and emerging issues in diagnostic endometrial cancer pathology that require the use of ancillary laboratory techniques, such as immunohistochemistry and molecular testing. The authors present the common diagnostic problems in endometrial carcinoma pathology, types of endometrial carcinoma, description of tissue testing and markers, pathological features, and targeted therapy.

Keywords: Lynch Syndrome; endometrial cancer; targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Typical immunohistochemical expression pattern for an endometrial endometrioid adenocarcinoma
Endometrioid-type endometrial adenocarcinoma (A, representative H&E stain) is usually strongly and diffusely positive for vimentin (B), negative for monoclonal CEA (C), positive for ER (D), and has patchy positive expression of p16 (E). Higher grade endometrioid tumors may lose some nuclear ER expression, but even the grade 3 endometrioid tumors will have at least some ER expression.
Figure 2
Figure 2. Typical immunohistochemical expression pattern for an endocervical adenocarcinoma
In biopsies, it can frequently be difficult to distinguish an endocervical adenocarcinoma from an endometrial adenocarcinoma. This distinction is important, as the surgical approaches can differ between the two tumor types. Endocervical adenocarcinoma (A, representative H&E) is usually negative for vimentin (B; strong staining in left portion of figure is stroma), strongly positive for monoclonal CEA (C), negative for ER (D), and diffusely positive for p16 (E).
Figure 3
Figure 3. Hysterectomy specimen with mucinous adenocarcinoma involving the endocervix and lower uterine segment
Unfortunately, immunohistochemistry cannot always resolve difficult pathology diagnostic problems. Based on the gross examination and examination of H&E stained slides (A), the differential diagnosis of this tumor includes endocervical adenocarcinoma, endometrial endometrioid adenocarcinoma with mucinous differentiation, and metastatic colorectal adenocarcinoma. The tumor was negative for cytokeratin 20 (B) and strongly positive for cytokeratin 7(C). While this profile favors a gynecological origin for this tumor, it must be remembered that a subset of MSI-High colorectal adenocarcinomas can express CK 7(109). The tumor was negative for vimentin and ER and had weak and patchy nuclear expression of CDX2, patchy expression of p16, and strong expression for CEA (data not shown). The immunohistochemistry profile therefore could not definitively establish a primary site for this malignancy. A subsequent colonoscopy was negative, so this tumor most likely represents a primary endocervical or endometrial adenocarcinoma. An endocervical primary may be favored because of the lack of ER and vimentin expression.
Figure 4
Figure 4. Uterine serous carcinoma
This serous carcinoma (representative H&E, A) shows a typical immunohistochemical expression pattern. The tumor has strong and diffuse nuclear expression of p53 (B) and p16 (C). WT-1 is positive (nuclear) in most ovarian high grade serous carcinomas. However, uterine serous carcinoma is usually negative for WT-1 (D). This tumor is ER positive (E).
Figure 5
Figure 5. Uterine serous carcinoma with atypical immunohistochemical expression pattern
By routine H&E staining (A), this tumor has features typical of uterine serous carcinoma, specifically high nuclear grade and loss of nuclear intra-epithelial polarity. However, the tumor is negative for p53 (B). The tumor did show strong and diffuse expression of p16 (C) and was negative for WT-1 (D). Unlike the serous carcinoma presented in Figure 4, this example is negative for ER (E).
Figure 6
Figure 6. MSI analysis chromatogram
In this example, the tumor has allelic shift for the microsatellites BAT26 and D17S250, as demonstrated by the extra peaks in the tumor tracings compared to that of normal tissue. The five other microsatellites in the panel had similar allelic shift, so this is an MSI-High endometrial carcinoma.
Figure 7
Figure 7. MLH1 methylation analysis
Extracted DNA is treated with bisulfite, which converts cytosine to uracil; methylated cytosines are resistant to such conversion, and this forms the basis of this assay. Concurrent analyses of control cell lines (top tracing, negative control K562; middle tracing, positive control RKO) are important. The endometrial tumor (bottom tracing) has both unmethylated and methylated MLH1. The unmethylated peak is likely due to the presence of contaminating normal stromal cells.
Figure 8
Figure 8. Immunohistochemical expression of DNA mismatch repair proteins in endometrial carcinoma
This tumor is negative for MSH2 (A) and has positive nuclear expression for MLH1 (B). In (A) note the presence of positive staining stromal cells. Such cells are a useful internal positive control.
Figure 9
Figure 9. Patterns of PTEN immunohistochemical expression seen in endometrial carcinoma
Positive (A), heterogeneous (B), and negative (C) examples are provided. In cases with PTEN negative staining, the presence of the positive staining stromal cells serves as a useful internal positive control.

Similar articles

Cited by

References

    1. McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002 Jan;21(1):11–5. - PubMed
    1. Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol. 1996 Feb;27(2):172–7. - PubMed
    1. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002 Jan;21(1):4–10. - PubMed
    1. Staebler A, Sherman ME, Zaino RJ, Ronnett BM. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol. 2002 Aug;26(8):998–1006. - PubMed
    1. Han CP, Lee MY, Kok LF, et al. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol. 2009 Sep;28(5):489–96. - PubMed